512. Does Time From COVID-19 Symptom Onset to Administration of Anti-spike Protein Monoclonal Antibody Predict Response?

BACKGROUND: Casirivimab/imdevimab is a monoclonal antibody (mAb) cocktail with emergency use authorization for mild-to-moderate coronavirus disease 2019 (Covid-19) in patients at high risk for severe disease progression and/or hospitalization. Little is known about the importance of early administra...

Descripción completa

Detalles Bibliográficos
Autores principales: SanFilippo, Savanna, Crovetto, Brynna, Milano, Marc, Bucek, John, Nahass, Ronald G, Brunetti, Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690614/
http://dx.doi.org/10.1093/ofid/ofab466.711

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690614/
http://dx.doi.org/10.1093/ofid/ofab466.711

Ejemplares similares